C ardiac troponin levels are routinely measured in clinical practice to diagnose myocardial infarction (MI), estimate the extent of myocardial necrosis, and identify patients that may benefit from therapies, such as early invasive management. 1 Peak troponin levels during MI have been shown to correlate with infarct size and left ventricular ejection fraction, 2 which are major determinants of mortality after infarction. 3 However, several 4-6 but not all studies 7,8 have demonstrated worse clinical outcomes with increasing levels of troponin in non-ST-segment-elevation acute coronary syndrome (NSTE ACS). NSTE ACS represents a heterogeneous population, in which timing of infarct onset is less certain and vessel occlusion and coronary flow, as well as treatment with and timing of revascularization, is more heterogeneous. The prognostic value of cardiac troponin levels after NSTE ACS, specifically as this relationship may be affected by early revascularization, is less well understood. To examine this issue, we analyzed data from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, 9 which provided a large and well-characterized cohort of patients with NSTE ACS. Our specific objective was to determine the prognostic relationship between peak troponin measurement during hospitalization and Background-In patients with non-ST-segment-elevation acute coronary syndrome (NSTE ACS), elevated troponin levels identify patients at high risk for adverse outcomes; however, it is unknown whether the magnitude of troponin elevation during hospitalization remains predictive of subsequent events in patients undergoing coronary revascularization.
Methods

Patient Population
The TRACER trial has been described previously in detail. 9 In brief, TRACER recruited 12 944 patients with NSTE ACS from 37 countries and 818 sites between December 2007 and June 2010; all patients had acute symptoms of coronary ischemia within 24 hours before hospital presentation and at least 1 of the following findings: a cardiac troponin (I or T) or creatine kinase-MB level that was higher than the upper limit of the normal range or new ST-segment depression of >0.1 mV or transient ST-segment elevation (<30 minutes) of >0.1 mV in at least 2 contiguous leads. Also, ≥1 of the following 4 criteria were required: age of ≥55 years; previous MI, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG); diabetes mellitus; or peripheral arterial disease. Patients were randomized to receive vorapaxar (loading dose 40 mg [given immediately after randomization and ≥1 hour before coronary revascularization] and daily maintenance dose 2.5 mg thereafter [to be continued for the entire study, with a minimum of 1 year]) or matching placebo stratified by the intention to use a glycoprotein IIb/IIIa inhibitor (versus none) and the intention to use a parenteral direct thrombin inhibitor (versus other antithrombin agents). As per study protocol, troponin (I or T) was measured before randomization, approximately every 8 hours for 24 hours after randomized assignment of study treatment, and daily during hospitalization until values returned to normal or until ≈72 hours after randomized assignment of study treatment, whichever occurred first. Performance and timing of cardiac catheterization and revascularization was at the discretion of the operating physician. The primary end point of the TRACER trial was a composite of death from cardiovascular causes, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization adjudicated by a clinical events committee according to prespecified criteria.
Peak Troponin Measurement
Given multiple commercially available assays for troponin used by participating TRACER hospitals with heterogeneity in local laboratory upper reference limit (URL), we used the ratio of peak troponin level divided by the local laboratory-defined URL (peak troponin ratio=peak troponin level/local laboratory URL). The use of this ratio to normalize cardiac troponin results from the various marker assays available in clinical practice has been used previously for clinical trial and registry database analyses. 4, 10 The peak troponin ratio during index hospitalization was determined for each individual patient who had at least 1 troponin sample collected during index hospitalization (n=12 635; 97.6%). For those patients treated with revascularization during index hospitalization, peak troponin ratio before the revascularization procedure was also determined.
Statistical Analysis
Peak troponin ratios were analyzed both as a categorical and continuous variable. Peak troponin ratio categories were ≤1, >1 to 3, >3 to 5, >5 to 10, >10 to 20, >20 to 50, and >50× URL. Baseline characteristics, features on presentation, and in-hospital management were reported by the peak troponin categories for patients treated with revascularization (PCI or CABG) during the index hospitalization and those treated medically without revascularization. As a continuous variable, the distribution of the peak troponin ratios was examined. To investigate the relationship between peak troponin ratios and clinical outcomes at 2 years post-index hospital discharge, cumulative event rates were estimated using the Kaplan-Meier method. Survival plots were generated, and log-rank tests were performed to compare the survival functions across peak troponin ratio categories. Cox proportional hazards regression modeling was used to examine the relationship between peak troponin ratio and the hazard of all-cause mortality at 2 years. Restricted cubic spline transformation was used when the relationship was nonlinear. The model was adjusted for important prognostic factors, including demographic characteristics (age, sex, race, and weight), medical history (smoking, hypertension, diabetes mellitus, hyperlipidemia, previous peripheral arterial disease, MI, stroke, PCI, and CABG), features on presentation (heart rate, blood pressure, ST-segment deviation, and Killip class), and treatment received (glycoprotein IIb/IIIa inhibitor, aspirin dose, and thienopyridine use). Results are presented as hazard ratios with 95% confidence intervals. The primary clinical outcome of interest was all-cause mortality. Other outcomes examined include death from cardiovascular cause, MI after hospital discharge, and stroke. MIs were also studied as spontaneous and procedure-related, as per the prespecified study definition. 9 To study whether the association between peak troponin ratio and all-cause mortality differs between patients treated with and without revascularization, an interaction term was included in the Cox model. Adjusted curves of predicted probability of mortality were created. In addition, an interaction term was added to determine whether the association between peak troponin ratio and all-cause mortality differed by mode of revascularization (CABG versus PCI). The primary analyses were based on the peak troponin ratio during index hospitalization until discharge. To gauge the possible confounding effect of troponin elevation because of revascularization procedure itself, sensitivity analyses were also performed using peak troponin ratio before the revascularization procedure.
All tests were 2-sided, and significance was established at the 0.05 level. No adjustment was made for multiple comparisons. SAS version 9.2 (SAS Institute, Cary, NC) was used to generate all statistical computations. The TRACER trial was approved by ethics committees or Institutional Review Boards for each participating site. All participants provided written informed consent.
Results
Baseline Patient Characteristics
Of the 12 635 study patients, revascularization was performed during index hospitalization in 8586 (68.0%) patients; 7299
WHAT IS KNOWN
• Compared with patients without troponin elevation, acute coronary syndrome patients with elevated troponin have more complex coronary lesions, a greater burden of intracoronary thrombus, and impaired tissue-level myocardial flow.
• Peak troponin levels during non-ST-segment-elevation acute coronary syndrome correlate with infarct size and left ventricular ejection fraction, which are major determinants of mortality after infarction.
• Early angiography followed by revascularization when appropriate is associated with improvement in clinical outcomes, including cardiovascular death and myocardial infarction in non-ST-segment-elevation acute coronary syndrome.
WHAT THE STUDY ADDS
• There is a marked differential relationship between the magnitude of troponin elevation and long-term mortality in patients with non-ST-segment-elevation acute coronary syndrome treated with and without revascularization.
• Although prognostically important in patients treated without revascularization, the prognostic implications of peak troponin level seem to be minimal in revascularized patients.
were treated with PCI alone, 1246 were treated with CABG alone, and 41 received both PCI and CABG. Median (25th, 75th percentiles) time to PCI after presentation was 39 (23, 72) hours and to CABG was 160 (86, 259) hours. Clinical characteristics and procedural findings of the overall study population stratified by in-hospital revascularization are shown in Table 1 . Compared with patients that did not undergo revascularization, those treated with revascularization during index hospitalization were more likely to be male, white, and of higher body weight as well as having ST-segment depression on presenting ECG, and were less likely to have previous MI and previous CABG. Revascularized patients more often had multivessel disease as compared with those undergoing catheterization in the nonrevascularized group (49.6% versus 28.5%).
The median (25th and 75th percentiles) number of troponin measurements per patient was 7 (5, 9) . Overall, the median (25th and 75th percentiles) peak troponin ratio during index hospitalization was 17.8 (4.7, 62.5); 6.7% of patients had a peak troponin level that was less than the URL. The median (25th and 75th percentiles) number of troponin measurements during hospitalization was 6 (5, 8) among revascularized patients and 5 (4, 7) among nonrevascularized patients. Revascularized patients had higher peak troponin ratios (median, 23 versus 9.5× URL). Among those treated with revascularization, troponin level peaked before revascularization in 4808 patients (56%) and after revascularization in 3778 patients (44%). There were relatively few differences in baseline characteristics in patients with increasing levels of inhospital peak troponin ratio. Both for patients treated without (Appendix I in the Data Supplement) and with (Appendix II in the Data Supplement) revascularization during index hospitalization, those with higher levels of in-hospital peak troponin were less likely to have previous PCI and more likely to present with ST-segment changes and higher Killip class, and have multivessel disease on angiography. Thienopyridine use at discharge was similar across peak troponin categories. Figure 1 demonstrates death rates stratified by overall peak troponin ratio during index hospitalization and in-hospital revascularization status. There was a differential relationship between peak troponin ratio and all-cause mortality at 2 years among patients treated without revascularization versus those treated with revascularization (P for interaction=0.004). Mortality rates were higher with increasing peak troponin ratio among nonrevascularized patients ( Figure 1A ; log-rank P=0.001); however, among patients treated with revascularization during index hospitalization, mortality rates at 2 years were similar irrespective of peak troponin ratio ( Figure 1B ; log-rank P=0.23). This differential relationship remained unchanged even when peak troponin measurements were limited to before revascularization ( Figure 1C ; log-rank P=0.88) and after multivariable adjustment (Figure 2 ). In addition, among revascularized patients, the relationship between peak troponin ratio and all-cause mortality was consistent regardless of the mode of revascularization (P for interaction=0.62).
Peak Troponin Ratio and Clinical Outcomes
The relationship between overall peak troponin ratio during index hospitalization and other clinical outcomes is shown in Table 2 . Cardiovascular death rates increased with CABG indicates coronary artery bypass grafting; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; and TIMI, thrombolysis in myocardial infarction. *P<0.05. Troponin, Mortality, and Acute Coronary Syndromes increasing peak troponin ratio among nonrevascularized patients (P<0.0001), but not among revascularized patients (P=0.26). Although there was variability, no clear trend was observed in MI rates with increasing peak troponin ratio among nonrevascularized patients (P=0.07). Overall, rates of MI were lower among revascularized patients compared with nonrevascularized patients, driven by lower spontaneous recurrent MI, but did not vary with increasing peak troponin levels (P=0.21). There was no difference in stroke rates with increasing troponin ratio among revascularized or nonrevascularized patients.
Discussion
In this large cohort of >12 000 patients with NSTE ACS, increasing long-term mortality was observed with increasing levels of peak cardiac troponin during hospitalization among those treated medically without revascularization. However, among those treated with revascularization, mortality in the Figure 1 . Kaplan-Meier mortality estimates by peak troponin ratio category. A, No revascularization (log-rank P value=0.001). B, Revascularization (peak troponin during index hospitalization; log-rank P value=0.23). Troponin, Mortality, and Acute Coronary Syndromes long term was similar irrespective of the magnitude of peak troponin level during index hospitalization whether the peak occurred before or after the procedure. Rates of MI were lower among revascularized patients compared with nonrevascularized patients, driven by lower spontaneous recurrent MI, but did not vary with increasing peak troponin levels. These results indicate that in patients with NSTE ACS, revascularization during index hospitalization attenuates the adverse prognostic importance of in-hospital peak troponin level, potentially at least, in part, by reduction in recurrent MI. Peak troponin levels during MI have been shown to correlate with infarct size and left ventricular ejection fraction, 2 which are major determinants of mortality after MI. 3 Although increased mortality at the highest levels of troponin might be a consequence of myocardial damage large enough to cause decreased left ventricular function, this cannot explain the greater risk of death in patients with only minor elevations of troponin where left ventricular function is preserved. Previous studies of patients with high-risk ACS found that any troponin concentrations above the level of assay detection were associated with increased risk 1, 11, 12 ; this is an observation consistent with the current recommendation that, in the proper setting, any detectable troponin using a diagnostic cut-off value >99th percentile should be considered pathological and indicative of MI. 13 However, studies performed in lower risk patient populations found no significant increase in cardiac event rate with minor elevations in troponin compared with the absence of detectable troponin. 8, [14] [15] [16] Thus, it has been suggested that troponin elevations are, in and of themselves, not equivalent, and it is the pathogenesis behind the elevation that is of prognostic importance. 17 Results of our study provide additional clarity about the discrepancy in the literature in the prognostic association of troponin levels in NSTE ACS. Several 4-6 but not all studies 7, 8 have demonstrated worse clinical outcomes with increasing levels of troponin in NSTE ACS. Despite heterogeneity in study populations, troponin assay used, and timing of troponin measurement, similar to our study, in the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) study, a strong association was observed between baseline level of high-sensitivity troponin T and the risk of cardiovascular death in patients with NSTE ACS managed without in-hospital revascularization, but such a relation was not observed in patients who underwent revascularization. 18 Furthermore, in the Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy (TACTICS)-TIMI 18 study, Cannon et al 7 also observed that troponin T may lose its predictive value with early invasive management.
Compared with patients without troponin elevation, NSTE ACS patients with elevated troponin have been shown to have more complex coronary lesions, a greater burden of intracoronary thrombus, and impaired tissue-level myocardial flow [19] [20] [21] ; these are features associated with a greater risk of death and MI, 22 probably explaining the prognostic value of elevated troponin. In a post hoc analysis of the FRISC II study, outcomes of patients with elevated troponin T levels and normal coronaries (<50% stenosis) were significantly better than patients with corresponding troponin T levels in the noninvasive cohort, and no different from those with normal coronary arteries and no troponin T elevation. 21 Similar to our analysis, there was a curvilinear trend in the rate of death with increasing levels of troponin T. However, the risks of MI and revascularization were the lowest in the lowest, modest in the highest, and highest in the 2 intermediate troponin T groups. In this study, there was a high incidence of total or subtotal occlusions, especially in the circumflex artery Figure 1 (Continued) . C, Revascularization (peak troponin before revascularization; log-rank P value=0.88). Troponin, Mortality, and Acute Coronary Syndromes or its branches, in the group with the highest troponin T levels, suggesting that many of the patients in this group might have had a transmural infarction that was undetected by the standard 12-lead ECG. The higher rate of completed infarctions at the highest troponin T levels might explain the lower risk of reinfarction and lower need for revascularization, but greatest risk of death. Thus, unlike ST-segment-elevation MI, troponin level in NSTE ACS is reflective not only of the size of the infarct but also the underlying burden of disease. There was no consistent pattern between troponin level and baseline patient characteristics associated with increased risk of adverse events, suggesting that the relation between troponin level and baseline characteristics is unlikely to be a major determinant of the prognostic value of troponin, especially as troponin remained an independent prognostic factor in multivariable analysis.
Angiography followed by revascularization when appropriate has been associated with improvement in clinical outcomes, including cardiovascular death and MI in NSTE ACS, 23 particularly among those patients at highest risk, including those with elevated troponin. 1, 6 Revascularization addresses underlying coronary anatomy, which, as discussed, correlates with troponin level and is recognized to be a major determinant of adverse outcomes in NSTE ACS. After revascularization, the effect of the size of the initial insult on prognosis seems to be relatively small. In contrast, among nonrevascularized patients, peak troponin remains an independent marker of prognosis. These findings may help to guide future risk stratification algorithms for patients with acute MI and may contribute to more efficient use of serial cardiac marker measurements in clinical practice.
Limitations
This analysis has several limitations. The study was retrospective and observational, and there may be unmeasured factors that could explain the observed differences in mortality. Although these findings are relevant to patients with typical clinical presentation of NSTE ACS, caution should be exercised in generalizing the results to patients with a low clinical suspicion of acute myocardial ischemia. Given that not all patients in the study cohort underwent a coronary angiogram, the burden of atherosclerotic disease, an important prognostic marker, could not be adjusted for in the model. The troponin samples were analyzed in multiple laboratories using different assays. Data on the specific type of troponin (I or T and usual or high sensitivity) was not collected. This variability also would reduce the ability to detect differences, and we attempted to adjust for it by expressing the value as multiples of the laboratory's URL. We used each patient's highest troponin level and did not take into account multiple infarctions. Given the heterogeneous nature of the population with NSTE ACS and the variable delay in presentation after symptom onset, the true peak troponin may not be reliably ascertained, despite the prespecified study protocol for timing of troponin collection. The decision to perform revascularization was at the discretion of the treating physician and not random. The impact of peak troponin ratio on the physician's decision to revascularize cannot be ascertained. Finally, early deaths, which occurred before patients could reach their true peak troponin level, would be counted in a lower peak troponin category. This categorization would tend to bias the results in the direction of lower troponin categories being associated with worse outcomes; however, our primary findings were in the opposite direction. This bias may, however, work in several directions, as patients dying before or without revascularization would be classified in the nonrevascularized group.
Conclusions
There is a differential relationship between the magnitude of peak troponin ratio and long-term mortality among patients with NSTE ACS treated with and without revascularization during index hospitalization. Although prognostically important in patients treated medically, the implications of peak troponin level seem to be minimal after early revascularization.
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